Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Making the correct diagnosis of an iris–ciliary body tumor can be challenging. A 35-year-old woman sought care because of a growing amelanotic lesion that destroyed the iris root and produced a large ciliary body mass. She had a history of systemic lupus erythematosus. The tumor was completely removed with an iridocyclectomy, which revealed that the plasma cells had been producing a large amount of amyloid. To our knowledge, this is the first description of an amyloid lesion simulating a solid intraocular tumor.
Amyloid involvement of ophthalmic structures is uncommon and rarely simulates a neoplasm. We and others have reported involvement of the vitreous in familial and nonfamilial primary amyloidosis; this process could be confused with an intraocular lymphoma.1,2 Similarly, there are several reported cases of conjunctival, eyelid, or orbital amyloid tumefactions.3,4 Rarely, amyloid can also be found infiltrating the anterior chamber angle or sclera, but no amyloid lesions simulating a solid intraocular tumor have been reported.5,6
The differential diagnosis of focal iris–ciliary body tumors is relatively straightforward. The majority of cases are uveal melanomas; less commonly, benign cystic lesions, melanocytomas, smooth muscle tumors, juvenile xanthogranuloma, Fuchs adenoma, primary carcinomas, medulloepitheliomas, lymphoid masses, neurofibromas, and metastases have been reported.3 We describe a unique case of a growing iris–ciliary body tumor that was shown, after excision with an iridocyclectomy, to be a plasma cell proliferation with a secondary amyloid deposit.
This 35-year-old woman had a 2-year history of a right iris–ciliary body growth and a 2-month history of decreased right eye vision. Her medical history was significant for systemic lupus erythematosus vasculitis, muscle pain, and both joint and facial swelling. She managed her symptoms with holistic medicines and was in remission with a negative anti-nuclear antibody. Aside from easy bruisability, she stated that she was currently in good health. None of the holistic medicines, based on a computer search, were associated with amyloid deposition.
On examination, the visual acuity was 20/50 OD with current correction and 20/30 OS. The left anterior segment was unremarkable and the intraocular pressures were 18 OU. From the 3- to 5-o’clock position in the right eye, there was an amelanotic iris–ciliary body mass with minimal posterior pigment epithelial proliferation at the edges (Figure 1). The bilobed amelanotic mass predominantly involved the ciliary body with erosion through the iris root. The pupillary margin was not distorted. There was no altered iris vasculature or lens opacity. The angle had no neovascularization. The fundi were unremarkable.
A, An amelanotic iris–ciliary body tumor that appears to erode through the iris root. B, Gonioscopic photograph shows a multilobed ciliary body mass.
An iris angiogram did not show a marked leakage or any intrinsic tumor vasculature. A large iris–ciliary body mass (Figure 2) was visible on high-frequency ultrasound. An iridocyclectomy was performed with complete removal of this mass.
High-frequency ultrasound shows that the major portion of this mass involves the ciliary body.
On gross examination, the mass appeared to be a ciliary body tumor with iris involvement. It was 6 × 5 × 3 mm. There were no ciliary process cysts. Beneath the ciliary epithelium, a tumor was composed of atypical plasma cells (Figure 3A), scattered lymphocytes, and a large amount of homogeneous eosinophilic material that was stained with crystal violet and Congo red (Figure 3B) and showed slight apple-green birefringence. It was strongly positive for κ light chains (Figure 4A) and negative for λ chains (Figure 4B). The pleomorphic plasma cells were stained with CD 138 (Figure 4C) and CD 79a (Figure 4D). The results of an amyloid A stain and CD20 stain were negative.
A, Pleomorphic plasma cells surrounded by a homogeneous eosinophilic material (hematoxylin-eosin, original magnification × 100) and stained with Congo red (B) (original magnification × 50).
A, κ light chain antigen (original magnification × 50). B, λ light chain antigen (original magnification × 50). C, CD138 stain (original magnification × 50). D, CD 79a stain (original magnification × 50).
These histologic features were consistent with a diagnosis of plasmacytoma of the ciliary body with early amyloid deposition and κ light chain deposition. The pleomorphic plasma cells were negative for a general B-cell antigen, which is usually absent on plasma cells, but were positive for a more differentiated B-cell antigen (CD 79a) and a plasma cell antigen (CD138). The plasma cells and the homogeneous protein deposit expressed a monoclonal κ light chain antigen.
Test results for a complete blood cell count, antinuclear antibody, immunoelectrophoresis, protein electrophoresis, and 24-hour urine collection for Bence-Jones proteins were all negative. Based on these negative results and the advice of 2 medical oncologists, no bone imaging was performed.
The differential diagnosis of iris–ciliary body tumors is usually straightforward but has a higher diagnostic error rate than posterior uveal masses.3 In our case, the history, physical findings, and ancillary testing suggested that more common entities such as melanomas, melanocytomas, metastases, and cystic lesions were not the cause of this lesion. The 2-year history of growth and slow visual loss made a metastatic lesion unlikely. The lesion was completely amelanotic, unlike most melanomas or melanocytomas; fluorescein angiography revealed no intrinsic tumor circulation, which is often noted with melanomas of this size. There was no cystic component to the lesion visible on high-frequency ultrasound. Preoperatively, we suspected that this most likely represented a benign smooth muscle tumor that had eroded through the iris root.
Amyloid can occur as a localized ocular or widespread systemic process. Approximately 4% of amyloid deposits in the head and neck region involve the orbit.7 Amyloid deposits in ophthalmic structures can occur as a primary or secondary process.1,4 Primary deposits (which can be familial or sporadic) occur in the absence of an associated disease. Secondary deposits have been noted after a myriad of processes, including trauma, infection, myeloproliferative disorders, and immune-mediated diseases. Most of the reported ophthalmic cases have been in association with familial amyloidosis with systemic involvement. Some cases have been noted to have only ophthalmic deposition of amyloid without evidence of systemic disease. Amyloid deposits in association with myeloproliferative entities such as lymphomas or plasma cell proliferations can produce paraproteinemias and involve the eye. In our case, the negative study results make this entity unlikely at present. In patients with extraosseous plasmacytoma, a myeloma develops within 10 years in 10% to 30% compared with 55% in patients with osseous plasmacytomas.8
Amyloid deposits can also occur in association with rheumatologic diseases, although involvement with systemic lupus erythematosus is distinctly uncommon.9 Our patient has either a primary amyloid deposit from an extraosseous plasmacytoma or a focal iris–ciliary amyloid deposit in association with systemic lupus erythematous. It is conceivable that benign but aberrantly localized plasma cells are part of the systemic lupus erythematosus process in this patient. Alternatively, there is an increase in lymphomas in patients with systemic lupus erythematosus, even when they are not treated with immunosuppression.10 Amyloid in association with systemic lupus erythematosus is quite rare and usually manifests as renal involvement. Fewer than 20 cases have been reported.8
This case illustrates the problem, despite newer diagnostic techniques, of potential diagnostic errors in anterior uveal tumor diagnosis. Our patient is probably at risk for local and systemic recurrence and is being closely observed.
Correspondence: Dr Char, 45 Castro St, Suite 309, San Francisco, CA 94114 (email@example.com).
Financial Disclosure: None.
Funding/Support: This study was supported in part by a grant from the Tumori Foundation.
Char DH, Crawford JB, Howes E, Carolan JA. Amyloid Mass of the Ciliary Body. Arch Ophthalmol. 2006;124(6):908-910. doi:10.1001/archopht.124.6.908